CA
NZ
UK
AU
IND
US
Vistagen Therapeutics, Inc. (NASDAQ: VTGN) reported a net loss of $13 million for the first quarter of fiscal year 2027, which ended on June 30, 2026. This loss reflects an improvement compared to a net loss of $15.1 million for the same period the …
Vycor Medical Inc. (OTC: VYCO) reported a significant revenue decline for the quarter ending June 30, 2026, totaling $418,264. This marked a 17% decrease compared to the same period in 2025, showcasing ongoing challenges, particularly in international markets where the company has been experiencing …
Quince Therapeutics (NASDAQ: QNCX) announced a $115 million private placement that lifted cash reserves to $116 million, extending its financial runway to the close of 2028 while simultaneously integrating Orphai Therapeutics’ LAM-001 program. These developments give investors a clearer view of funding availability and …
RadNet (NASDAQ: RDNT) expanded its equity offering by registering the resale of up to 34,069 common shares, each carrying a $0.0001 par value, through an automatic shelf registration on August 14, 2026. The registration targets the share component of payments required to meet milestone …
Replimune reported that its cash and short‑term investments total $195.3 million, a balance bolstered by a recent $150 million financing round and $141.0 million in net proceeds from a common stock issuance. This liquidity cushion equates to more than twelve months of operating runway, …
Silexion Therapeutics Corp. has successfully transitioned its candidate SIL204 into a Phase 2/3 clinical trial targeting locally advanced pancreatic cancer, with trial initiation occurring on July 29, 2026, at Tel Aviv Sourasky Medical Center. The overlapping authorizations demonstrate Silexion’s strategic approach to streamlining its …
Skye Bioscience, Inc. (NASDAQ: SKYE) is poised to strengthen its position in the healthcare market through the acquisition of Redx Pharma Limited. ThisMergeris designed to occur via a scheme of arrangement, contingent uponShareholderapproval from both companies. This acquisition not only facilitates growth but also …
Neumora Therapeutics, Inc. (NASDAQ: NMRA) announced significant leadership changes alongside its second-quarter financial results for the period ended June 30, 2026. Effective August 14, 2026, Joshua Pinto, Ph.D. Will step into the role of Chief Executive Officer, succeeding Paul L. Berns, who will assume …
OPKO Health (NASDAQ: OPK), Inc. has successfully secured an additional $125 million by amending its existing Note Purchase Agreement. This move enhances its financial flexibility, enabling the healthcare company to pursue further investment opportunities. This capital will contribute to future growth initiatives, especially as …
The shift is attributed to lowered costs associated with contract research and finance support. The company’s financial position also includes cash, cash equivalents, and marketable securities amounting to $79.4 million, providing necessaryLiquiditythrough the second quarter of 2027. This strengthened cash runway is important as …
Please wait processing your request...